These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35238626)

  • 1. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
    Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
    J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
    Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
    JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
    McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
    JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
    O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Musser BJ; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Brown ER; Heirman I; Davis JD; Turner KC; Ramesh D; Mahmood A; Hooper AT; Hamilton JD; Kim Y; Purcell LA; Baum A; Kyratsous CA; Krainson J; Perez-Perez R; Mohseni R; Kowal B; DiCioccio AT; Geba GP; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD; Weinreich DM;
    JAMA; 2022 Feb; 327(5):432-441. PubMed ID: 35029629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
    Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
    JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
    Bierle DM; Ganesh R; Razonable RR
    J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
    J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
    J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
    Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Ishii T; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Kanbe T; Kanzaki N; Azuma T; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Tsukada Y; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Umeda T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Iseki K
    Int J Med Sci; 2022; 19(5):834-841. PubMed ID: 35693744
    [No Abstract]   [Full Text] [Related]  

  • 14. Casirivimab/Imdevimab: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
    Riccardo BA; Gabriele S; Nunzia E; Isabella DF; Biagio P; Maria F; Emanuela Z; Agnese G; Nicola SM; Giulio V; Riccardo S; Giuseppe B; Ivan G
    Am J Perinatol; 2024 May; 41(S 01):e612-e616. PubMed ID: 35973799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
    Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
    Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
    Buonomo AR; Filippo ID; Esposito N; Saccone G; Nobile M; Viceconte G; Villari R; Carlo CD; Bifulco G; Gentile I
    Am J Perinatol; 2024 Feb; 41(3):365-367. PubMed ID: 37072016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.
    Sloan B; Duhaime E; Sandkovsky U; Berhe M
    Proc (Bayl Univ Med Cent); 2022; 35(3):339-341. PubMed ID: 35518791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report of COVID-19 Infection After Kidney Transplant Treated With Casirivimab-Imdevimab and Mycophenolate Mofetil Changed to Everolimus.
    Kijima Y; Shimizu T; Kato S; Kano K; Horiuchi T; Nozaki T; Omoto K; Inui M; Toma H; Iida S; Takagi T
    Transplant Proc; 2022; 54(6):1561-1563. PubMed ID: 35065832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.